Join the Enhertu group to help and get support from people like you.
Enhertu News
FDA Approval Expands Earlier Use of Enhertu for Metastatic Breast Cancer
MONDAY, Feb. 3, 2025 – The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with unresectable or metastatic hormone receptor ...
Enhertu Approved as First HER2-Directed Therapy for Patients with HER2-Low or HER2-Ultralow Metastatic Breast Cancer
27 January 2025 – AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (...
New Hope Against Breast Cancers That Spread to the Brain
TUESDAY, Oct. 8, 2024 – A recently approved targeted chemotherapy drug can significantly extend the lives of advanced breast cancer patients who have developed tumors in their brains, new clinical...
Enhertu Approved in the US as First Tumor-Agnostic HER2-Directed Therapy for Previously Treated Patients with Metastatic HER2-Positive Solid Tumors
April 6, 2024 – AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC...
Enhertu Approved in the US as the First HER2-Directed Therapy for Patients with Previously Treated HER2-Mutant Metastatic Non-Small Cell Lung Cancer
Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease 12 August 2022 – A...
Enhertu Approved in the US as the First HER2-Directed Therapy for Patients with HER2-Low Metastatic Breast Cancer
Based on DESTINY-Breast04 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reduced risk of disease progression or death by 50% and increased overall survival by more than six months v...
Enhertu Approved in the US for Patients with HER2-Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen
Approval broadens indication for AstraZeneca and Daiichi Sankyo’s Enhertu to earlier use in metastatic breast cancer Based on ground-breaking DESTINY-Breast03 results showing Enhertu reduced the r...
Enhertu Approved in the U.S. for the Treatment of Patients With Previously Treated HER2 Positive Advanced Gastric Cancer
TOKYO & MUNICH & BASKING RIDGE, N.J.--(BUSINESS WIRE) January 15, 2021 – Daiichi Sankyo Company, Ltd. (hereafter, Daiichi Sankyo) and AstraZeneca’s Enhertu (fam-trastuzumab deruxtecan-nxki) has be...
FDA Approves Enhertu (fam-trastuzumab deruxtecan-nxki) for HER2-Positive Unresectable or Metastatic Breast Cancer Following Two or More Prior Anti-HER2 Based Regimens
20 December 2019 – AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today announced that the US Food and Drug Administration (FDA) has approved Enhertu® (fam-trastuzumab ...
Further information
Related condition support groups
Breast Cancer, Metastatic, Non-Small Cell Lung Cancer, Breast Cancer, Gastric Cancer